Sildenafil (Viagra) and ophthalmology

Survey of Ophthalmology

Volumn 44, Issue 2, 1999, Pages 153-162

  Marmor, Michael F ^a,b   Kessler, Robert ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Cyclic guanosine monophosphate; Drug toxicity; Impotence; Phosphodiesterase; Retina; Retinovascular accidents; Sildenafil citrate; Viagra

Indexed keywords

CYCLIC GMP; NITRIC ACID DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL;

CARDIOVASCULAR DISEASE; CORPUS CAVERNOSUM; DRUG CONTRAINDICATION; DRUG SAFETY; HAZE; HUMAN; IMPOTENCE; PENIS ERECTION; PRIORITY JOURNAL; RETINA INJURY; REVIEW; VISUAL DISORDER;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; HUMANS; IMPOTENCE; OPHTHALMOLOGY; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RETINA; RETINAL DISEASES; SAFETY; VISUAL ACUITY;

EID: 0033199357     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(99)00079-X     Document Type: Review

References (41)

1. Aquirre G, Farber D, Lolley R, et al: Rod-cone dysplasia in Irish setters: a defect in cyclic GMP metabolism in visual cells. Science 201:1133-4, 1978
2. Borillo D: Dangers of Viagra use in pilots: AMEs should become familiar with the detrimental side-effects of sildenafil. Federal Air Surgeons Med Bull Fall 1998
3. Danciger M, BlaneyJ, Gao YQ, et al: Mutations in the PDE6B gene in autosomal recessive retinitis pigmentosa. Genomics 30:1-7, 1995
4. Donahue SP, Taylor RJ: Pupil-sparing third nerve palsy associated with sildenafil citrate (Viagra). Am J Ophthalmol 126: 476-7, 1998
5. Dryja TP, Rucinski DE, Chen SH, Berson EL: Frequency of mutations in the gene encoding the a subunit of rod cGMP-phosphodiesterase in autosomal recessive retinitis pigmentosa. Invest Ophthalmol Vis Sci 40:1859-65, 1999
6. Estrade M, Grondin P, Cluzel J, et al: Effect of a cGMP-specific phosphodiesterase inhibitor on retinal function. Eur J Pharmacol 352:157-63, 1998
7. Farber DB, Lolley RN: Cyclic guanosine monophosphate: elevation in degenerating photoreceptor cells of the C3H mouse retina. Science 186:449-51, 1974
8. Food and Drug Administration Joint Clinical Review, 8 May 1998. Amendment to clinical review of 22 January 1998: Effects of sildenafil on the electroretinogram in Study 148-232
9. Food and Drug Administration Joint Clinical Review. Animal Pharmacology: Mechanism of action, p 4
10. Food and Drug Administration Joint Clinical Review. Study 101/101B: A randomized, double-blind, placebo controlled, parallel-group, fixed-dose, multicenter, long-term dose-response study to assess the efficacy and safety of sildenafil (UK-92, 480) administered prior to sexual activity to male patients with erectile dysfunction, pp 99-102
11. Food and Drug Administration Joint Clinical Review. Study 148-004: Phase I investigator-blind, placebo-controlled, evaluation of safety, toleration, and pharmacokinetics of sildenafil following escalating single oral doses in healthy male volunteers, pp 96-98
12. Food and Drug Administration Joint Clinical Review. Study 148-102: A double-blind, randomized, placebo-controlled, parallel group, fixed-dose, multicenter study to asses the efficacy and safety of UK-92,480 administered over six months to male patients with erectile dysfunction, pp 104-110
13. Food and Drug Administration Joint Clinical Review. Study 148-103: A double-blind, randomized, placebo-controlled, parallel group, multicenter, flexible dose escalation study to assess the efficacy and safety of sildenafil administered as required to male patients with erectile dysfunction, pp 111-117
14. Food and Drug Administration Joint Clinical Review. Study 148-104: A double-blind, randomized, placebo-controlled, parallel group, multicenter, flexible dose escalation study to assess the efficacy and safety of sildenafil administered as required to male diabetic patients with erectile dysfunction, pp 118-123
15. Food and Drug Administration Joint Clinical Review. Study 148-223: A double-blind, randomized, placebo-controlled, four period crossover study to assess the effect of orally administered sildenafil (50, 100 and 200 mg) on visual function in healthy male volunteers, pp 160-161
16. Food and Drug Administration Joint Clinical Review. Study 148-228: An open, randomized, single oral dose, four way crossover study to determine the dose proportionality of the pharmacokinetics of sildenafil in healthy male volunteers over the dose range 25 mg to 200 mg, pp 167-169
17. Food and Drug Administration Joint Clinical Review. Study 148-232: A randomized, double-blind, placebo-controlled, crossover pilot study to investigate the effects of a single oral table dose of sildenafil (200 mg) on visual function (electroretinogram, photostress, visual field and colour discrimination tests) in healthy male volunteers and patients with diabetic retinopathy
18. Food and Drug Administration Review and Evaluation of Pharmacology and Toxicology Data. Section 1.2.3.6 Pharmacology: Activities related to mechanism of action: Functional effects on other tissues expressing PDE5 enzyme: Retinal effects, 1998, pp 19-21
19. Food and Drug Administration Joint Clinical Review, Center for Drug Evaluation and Research, Division of Cardio-Renal Drug Products (HFD-110). Review and Evaluation of Pharmacology and Toxicology Data. NDA 20-895 (Viagra tablets [sildenafil citrate]). January 23, 1998
20. Food and Drug Administration Joint Clinical Review, Center for Drug Evaluation and Research. NDA 20-895 (Sildenafil for male impotence). January 22, 1998
21. Food and Drug Administration. Summary of reports of death in Viagra users received from marketing (late March) through mid-November 1998. http://www.fda.gov/cder/consumerinfo/viagra/safety3.htm
22. Goldstein I, Lue TF, Padma-Nathan H, et al: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group [see comments] [published erratum appears in N Englj Med 1998;339:59]. N Engl J Med 338:1397-404, 1998
23. 22a. Utinger RD: A pill for impotence. N Engl J Med 338:148-9, 1998
24. Grunwald JE, Koppiker NP, Hodges M, et al: Visual adverse events in patients with eye disorders who received sildenafil for the treatment of erectile dysfunction (abstract). Invest Ophthalmol Vis Sci 40(Suppl):S767, 1999
25. Kabalin JN, Kessler R: Five-year followup of the Scott inflatable penile prosthesis and comparison with semirigid penile prosthesis. J Urol 140:1428-30, 1988
26. Kloner RA, Jarow JP: Erectile dysfunction and sildenafil citrate and cardiologists [editorial]. Am J Cardiol 83:576-82, A7, 1999
27. Kretschmann U, Gockeln R, Meschi M, et al: Short time influences of sildenafil on visual function (abstract). Invest Ophthalmol Vis Sci 40(Suppl):S766, 1999
28. Laties A, Ellis P, Motion JD: The effects of sildenafil citrate (Viagra) on color discrimination in volunteers and patients with erectile dysfunction (abstract). Invest Ophthalmol Vis Sci 40(Suppl):S693, 1999
29. Laties AM, Fraunfelder FT: Ocular safety of Viagra (sildenafil citrate). Trans Am Ophthalmol Soc (in press)
30. Morales A, Gingell C, Collins M, et al: Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res 10:69-74, 1998
31. Nickas ME, Kessler R, Kabalin JN: Long-term experience with controlled expansion cylinders in the AMS 700CX inflatable penile prosthesis and comparison with earlier versions of the Scott inflatable penile prosthesis. Urology 44: 400-3, 1994
32. Rendell MS, Rajfer J, Wicker PA, Smith MD: Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group [see comments]. JAMA 281:421-6, 1999
33. Schneider T, Zrenner E. The influence of phosphodiesterase inhibitors on ERG and optic nerve response of the cat. Invest Ophthalmol Vis Sci 27:1395-403, 1986
34. Stryer L: Biochemistry. New York, WH Freeman, 1995, ed 4, pp 332-9
35. Vobig MA, Klotz T, Staak M, et al: Retinal side-effects of sildenafil. Lancet 353:375, 1442, 1999
36. Wallis RM, Corbin JD, Francis SH, Ellis P: Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 83:3C-12C, 1999
37. Wallis RM, Leishman D, Pullman L, Graepel P, Heywood R: Effects of sildenafil on retinal histopathology and electroretinogram (ERG) in dogs (abstract). Ophthalmic Res 30(Suppl): S68, 1998
38. Zrenner E: No cause for alarm over retinal side-effects of sildenafil [comment]. Lancet 353:340-1, 1999
39. Zrenner E: Electrophysiological characteristics of the blue sensitive mechanism: test of a model of cone interaction under physiological and pathological conditions. Doc Ophthalmol Proc Ser 33:103-25, 1982
40. Zrenner E, Kramer W, Bittner C, et al: Rapid effects on colour vision, following intravenous injection of a new, nonglycoside positive inotropic substance (AR-L 115 BS). Doc Ophthalmol Proc Ser 33:493-507, 1982
41. Zusman RM, Morales A, Classer DB, Osterloh IH: Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 83: 35C-44C, 1999